Display options
Cite
Uzun F, Biyik I, Akturk IF, et al. Antiplatelet resistance and the role of associated variables in stable patients treated with stenting. Postepy Kardiol Interwencyjnej. 2015;11(1):19-25doi: 10.5114/pwki.2015.49180.
Uzun, F., Biyik, I., Akturk, I. F., Erturk, M., Yalcin, A. A., Surgit, O., Oner, E., Pusuroglu, H., & Birand, A. (2015). Antiplatelet resistance and the role of associated variables in stable patients treated with stenting. Postepy w kardiologii interwencyjnej = Advances in interventional cardiology, 11(1), 19-25. https://doi.org/10.5114/pwki.2015.49180
Uzun, Fatih, et al. "Antiplatelet resistance and the role of associated variables in stable patients treated with stenting." Postepy w kardiologii interwencyjnej = Advances in interventional cardiology vol. 11,1 (2015): 19-25. doi: https://doi.org/10.5114/pwki.2015.49180
Uzun F, Biyik I, Akturk IF, Erturk M, Yalcin AA, Surgit O, Oner E, Pusuroglu H, Birand A. Antiplatelet resistance and the role of associated variables in stable patients treated with stenting. Postepy Kardiol Interwencyjnej. 2015;11(1):19-25. doi: 10.5114/pwki.2015.49180. Epub 2015 Mar 06. PMID: 25848366; PMCID: PMC4372627.
Copy Download .nbib Format: NLM
Share it on

Postepy Kardiol Interwencyjnej. 2015;11(1):19-25. doi: 10.5114/pwki.2015.49180. Epub 2015 Mar 06.

Antiplatelet resistance and the role of associated variables in stable patients treated with stenting.

Postepy w kardiologii interwencyjnej = Advances in interventional cardiology

Fatih Uzun, Ismail Biyik, Ibrahim Faruk Akturk, Mehmet Erturk, Ahmet Arif Yalcin, Ozgur Surgit, Ender Oner, Hamdi Pusuroglu, Ali Birand

Affiliations

  1. Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.
  2. Department of Cardiology, Usak State Hospital, Usak, Turkey.

PMID: 25848366 PMCID: PMC4372627 DOI: 10.5114/pwki.2015.49180

Abstract

INTRODUCTION: Nowadays, clopidogrel and acetylsalicylic acid (ASA) have become routinely applied therapies in percutaneous coronary interventions (PCI) with stenting.

AIM: Numerous variables can interfere with antiplatelet responsiveness, so we aimed to investigate the role of different variables associated with ASA or clopidogrel resistance in stable coronary artery disease.

MATERIAL AND METHODS: A total of 207 patients undergoing elective PCI were included in the analysis. All patients received a loading dose of clopidogrel and ASA during PCI procedure and followed by dual antiplatelet therapy. Clopidogrel and ASA resistance were measured by impedance aggregometry method.

RESULTS: Of the patients, 19.8% had clopidogrel resistance, 18.8% had ASA resistance, 9.2% had both clopidogrel and ASA resistance, and 71.5% were responsive to both drugs. In multivariate analysis, platelet count, angiotensin receptor blocker (ARB) use, and ASA resistance were independent variables associated with clopidogrel resistance, and clopidogrel resistance was the only variable associated with ASA resistance. In differentiating whether clopidogrel resistance exists or not, optimum ASA aggregometry response cut-off values were specified, and in differentiating whether ASA resistance exists or not, optimum clopidogrel aggregometry response cut-off values were specified.

CONCLUSIONS: In this study, there was a higher incidence of low responsiveness to ASA when there was a low response to clopidogrel, and vice versa. Angiotensin receptor blocker use, platelet count, and ASA resistance were independent variables associated with clopidogrel resistance. Clopidogrel resistance was the only independent variable associated with ASA resistance. Angiotensin receptor blocker use seems to an independent risk factor for clopidogrel resistance in this study, but this result needs to be verified in other studies.

Keywords: acetylsalicylic acid; angiotensin receptor blocker; clopidogrel; platelets; resistance

References

  1. J Am Coll Cardiol. 2003 Mar 19;41(6):961-5 - PubMed
  2. Arq Bras Cardiol. 2012 Dec;99(6):1135-41 - PubMed
  3. Clin Appl Thromb Hemost. 2015 Mar;21(2):166-71 - PubMed
  4. J Thromb Thrombolysis. 2014 May;37(4):469-74 - PubMed
  5. Thromb Haemost. 2003 May;89(5):783-7 - PubMed
  6. Thromb Haemost. 2010 Jan;103(1):151-9 - PubMed
  7. Anadolu Kardiyol Derg. 2013 Jun;13(4):370-3 - PubMed
  8. Can J Cardiol. 1995 Mar;11(3):221-7 - PubMed
  9. Circulation. 2006 Aug 22;114(8):838-54 - PubMed
  10. Am J Cardiol. 2001 Aug 1;88(3):230-5 - PubMed
  11. Circulation. 2002 Apr 9;105(14):1650-5 - PubMed
  12. Angiology. 2012 Jan;63(1):62-6 - PubMed
  13. Platelets. 2014;25(2):102-10 - PubMed
  14. Circulation. 2011 Dec 6;124(23):e574-651 - PubMed
  15. Eur J Intern Med. 2006 Aug;17(5):349-54 - PubMed
  16. Circulation. 1997 Jan 7;95(1):125-32 - PubMed
  17. J Cardiovasc Pharmacol. 2009 May;53(5):368-72 - PubMed
  18. J Am Coll Cardiol. 2009 Mar 10;53(10):849-56 - PubMed
  19. J Geriatr Cardiol. 2013 Mar;10(1):21-7 - PubMed
  20. Acta Neurol Scand. 2013 Oct;128(4):213-9 - PubMed
  21. Circulation. 2009 Jan 20;119(2):237-42 - PubMed
  22. Circulation. 2003 Jun 17;107(23):2908-13 - PubMed
  23. J Thromb Thrombolysis. 2012 May;33(4):349-54 - PubMed
  24. J Am Coll Cardiol. 2006 Jan 3;47(1):27-33 - PubMed
  25. Eur Heart J. 2004 Mar;25(6):476-83 - PubMed
  26. Clin Appl Thromb Hemost. 2014 Oct;20(7):749-54 - PubMed
  27. Eur Heart J. 2008 Apr;29(8):992-1000 - PubMed
  28. Curr Opin Pharmacol. 2013 Apr;13(2):242-50 - PubMed
  29. J Clin Pharm Ther. 2012 Dec;37(6):630-6 - PubMed
  30. J Nephrol. 2011 Sep-Oct;24(5):636-46 - PubMed
  31. Stroke Res Treat. 2013;2013:727842 - PubMed
  32. Platelets. 2014;25(6):447-51 - PubMed
  33. J Am Coll Cardiol. 2005 Jan 18;45(2):246-51 - PubMed
  34. Nephrol Dial Transplant. 2012 Apr;27(4):1460-6 - PubMed
  35. J Atheroscler Thromb. 2011;18(7):560-7 - PubMed

Publication Types